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AbstrACt
Introduction Automated insulin delivery (also known as 
closed loop, or artificial pancreas) has shown potential 
to improve glycaemic control and quality of life in people 
with type 1 diabetes (T1D). Automated insulin delivery 
devices incorporate an insulin pump with continuous 
glucose monitoring(CGM) and an algorithm, and adjust 
insulin in real time. This study aims to establish the safety 
and efficacy of a hybrid closed-loop (HCL) system in a 
long-term outpatient trial in people with T1D aged 12 
–<25 years of age, and compare outcomes with standard 
therapy for T1D as used in the contemporary community.
Methods and analysis This is an open-label, multicentre, 
6-month, randomised controlled home trial to test the
MiniMed Medtronic 670G system (HCL) in people with
T1D aged 12 –<25 years, and compare it to standard
care (multiple daily injections or continuous subcutaneous
insulin infusion (CSII), with or without CGM). Following
a run-in period including diabetes and carbohydrate
counting education, dosage optimisation and baseline
glucose control data collection, participants are
randomised to either HCL or to continue on their current
treatment regimen. The primary aim of the study is to
compare the proportion of time spent in target sensor
glucose range (3.9–10.0 mmol/L) on HCL versus standard
therapy. Secondary aims include a range of glucose control
parameters, psychosocial measures, health economic
measures, biomarker status, user/technology interactions
and healthcare professional expectations. Analysis will be
intention to treat. A study in adults with an aligned design
is being conducted in parallel to this trial.
Ethics and dissemination Ethics committee permissions
were gained from respective institutional review boards. 
The findings of the study will provide high-quality evidence
on the role of HCL in clinical practice.
IntroduCtIon 
Automated insulin delivery (also known as 
closed loop or ‘artificial pancreas’) systems 
consist of an insulin pump (CSII), a contin-
uous glucose monitor (CGM) and an 
algorithm that determines the automated 
insulin delivery. Single (insulin only) and dual 
(insulin and glucagon) systems have been 
developed. A variety of platforms exist using 
different combinations of insulin pumps, 
CGM and algorithms (there are three core 
algorithm constructs: (1) proportional inte-
grative derivative (PID),1 (2) model predic-
tive control2 and (3) fuzzy logic3). Hybrid 
closed-loop (HCL) systems use the algorithm 
to control background (or basal) insulin 
requirements while meal announcement 
with carbohydrate estimation and bolusing 
are still required to be entered manually by 
the user. The technical evolution in auto-
mated insulin delivery has been rapid, from 
proof of concept experiments in 20064 to the 
first commercial release of a single hormone 
hybrid system (MiniMed 670G, USA only, 
approved for those aged 14 years and over) 
in 2017.
strengths and limitations of this study
 ► This a long-term outpatient randomised controlled
home trial in people aged 12 –<25 years of age with 
type 1 diabetes (T1D)  comparing a hybrid closed-
loop (HCL) system to standard care.
 ► The secondary objectives are wide in scope, and will 
provide a full evaluation of the clinical application of
HCL technology for people with T1D.
 ► This study of people with diabetes aged 12–<25
years has glucose end-points aligned with a concur-
rent study examining HCL in adults >25 years old,
thereby facilitating comparison of metabolic out-
comes between these two populations.
 ► The technology is rapidly evolving, and results of this 
study may underestimate the future potential of au-
tomated insulin delivery systems.
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The development of automated insulin delivery has 
been driven by the goal of achieving improved time spent 
in target glucose range, while minimising hypoglycaemia. 
Long-term poor control is known to predict the devel-
opment of diabetes complications.5 However, despite 
improvements in diabetes education, insulin pharma-
cology, glucose monitoring and insulin delivery devices, 
fewer than a third of patients reach haemoglobin A1c 
(HbA1c) targets set by international guidelines.6 Further, 
adolescence and young adulthood are particularly high-
risk age groups, during which glycaemic control is at its 
poorest.6 The burden of managing diabetes is high for 
the patient and their caregivers, resulting in poor quality 
of life7 and high rates of psychological comorbidity.8 
Automated insulin delivery has the potential to improve 
glycaemic control and improve quality of life during this 
vulnerable period.
Due to the complex care required, development of 
complications and loss of productivity, type 1 diabetes 
(T1D) incurs a significant burden on healthcare 
budgets. In Australia, it is estimated that $A200 million 
per annum is spent on T1D.9 As the incidence of T1D 
is increasing,10 11 new approaches like automated insulin 
delivery are required to improve patient outcomes, and 
have the potential to reduce the economic impact.
To date, several outpatient studies using auto-
mated insulin delivery have been published. Although 
heterogeneous in design and with a variety of auto-
mated and semiautomated insulin±glucagon delivery 
systems employed, a meta-analysis of studies that were 
conducted at home, camps and in hotels demonstrated 
a 12.59% overall improvement in time spent in target 
range (3.9–10.0 mmol/L) when compared with stan-
dard insulin pump therapy (CSII) or sensor-augmented 
pump (SAP) therapy.12 The longest duration of follow-up 
for included studies was 12 weeks.13 This included two 
substudies: (1) a study in adults (n=33) who used the 
system 24 hours per day, and (2) a study in children 
and adolescents (n=25) who used the system overnight. 
Adults improved time in target range (3.9–10.0 mmol/L) 
by 11%, and the children and adolescents improved over-
night glucose time in target range (3.9–8.0 mmol/L) by 
24.7%.13 There are other large long-term multisite trials 
investigating closed-loop technology currently underway.
The only automated insulin delivery device that is 
currently commercially available is the MiniMed 670G, 
although only available in the USA and approved for 
people with T1DM aged above 14 years. A non-controlled 
pivotal safety study using this device in patients aged 14–75 
years (n=124) for 3 months demonstrated safety; in addi-
tion, diabetes control was improved and HbA1c reduced 
from 7.4% to 6.9%.14 Adolescent participants used the 
automated insulin delivery feature (‘Auto Mode’) 75.8% 
of the time and demonstrated a change in HbA1c from 
7.7%±0.8% to 7.1%±0.6%.15
Longer duration and controlled studies are required to 
quantify efficacy of the MiniMed 670G system. Our study 
is a 6-month multisite randomised controlled study that 
compares the Medtronic 670G system to standard therapy 
(CSII or multiple daily injections (MDI), with or without 
CGM). We will assess the impact on glucose control and 
quality of life, and conduct health economic analyses.
We hypothesise that the HCL MiniMed 670G system 
(HCL hereinafter) will improve the time spent in target 
glucose range by 7% compared with standard therapy 
(CSII or MDI, with or without CGM). We further 
hypothesise that HCL will reduce hypoglycaemia (time 
spent <3.9 mmol/L) by 60%. A number of other glucose 
control metrics (time spent in high glucose range, 
glucose variability, night-time glucose, daytime glucose) 
are hypothesised to improve, as well as quality of life 
measurements.
AIMs
The primary objective of the study is to compare the 
proportion of time that sensor glucose is in target range 
(3.9–10.0 mmol/L) using HCL versus standard therapy 
(CSII, MDI, with or without CGM), measured by masked 
CGM at 23–26 weeks post randomisation. The primary 
objective and secondary objectives are listed in table 1.
MEthods
This is a multicentre, unblinded, parallel, randomised 
controlled phase III home trial, conducted by five tertiary 
paediatric diabetes centres in Australia. The trial has 
been approved. Ethics approval for the other four sites 
(The Children’s Hospital at Westmead, Sydney, John 
Hunter Children’s Hospital, Newcastle, Royal Children’s 
Hospital, Melbourne, and Women’s and Children’s 
Hospital, Adelaide are covered by a National Ethics 
Application at the Women’s and Children’s Hospital 
(HREC/16/WCHN/100). The trial is prospectively 
registered with the Australian New Zealand Clinic Trials 
Registry (ACTRN12616000753459). Inclusion and exclu-
sion criteria are summarised in table 2.
Patient involvement
This study concept is a product of ongoing consumer 
engagement at the lead site (Princess Margaret Hospital) 
where the patients have advocated for the acceleration 
of automated insulin delivery systems. On a higher level, 
the Juvenile Diabetes Research Foundation (JDRF), 
which represents the T1D community have also called for 
research into these systems. The consumer engagement 
group at Princess Margaret Hospital (Perth) and JDRF 
were consulted throughout the study protocol develop-
ment, and hence assessed the burden of the intervention. 
Study results will be disseminated through open partici-
pant and community forums, lay and scientific presenta-
tions and in scientific journals.
We will study adolescents and young adults aged 12–<25 
years as this is a time that glycaemic control often deterio-
rates,6 highlighting the need for new treatment strategies. 
With an upper HbA1c cut-off of 10.5% (91mmol/mol), 
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we will exclude participants who are less likely to comply 
and adhere to the protocol. Participants are approached 
through multiple avenues including directly in clinic, 
email and phone recruitment and through online adver-
tising. Written informed consent is obtained from partic-
ipants aged ≥18 years, and written parental consent and 
participant assent for those <18 years. Consent is attained 
by the research nurse. A participant may decide to with-
draw from the study at any time without impacting future 
care. Once enrolled, the study duration is approximately 
7 months, including a 4–5-week run-in, and 26-week study 
phase from randomisation.
To estimate the total sample size, data from the JDRF 
CGM randomised controlled trial were used.16 In this 
Table 1 Primary and secondary objectives
Glucose control 
(24 hours, day (0600–
2400), night (0000–
0600))
1. CGM data:
a. % Time <2.8 mmol/L
b. % Time <3.3 mmol/L
c. % Time <3.9 mmol/L
d. % Time 3.9–7.8 mmol/L
e. % Time 3.9–10.0 mmol/L (primary outcome)
f. % Time>10.0 mmol/L
g. % Time>13.9 mmol/L
h. % Time>16.7 mmol/L
i. SD and coefficient of variation of CGM values
j. Mean glucose
2. Average fasting blood glucose (mmol/L, Defined as fasting capillary blood glucose level on waking
(between 5am and 9am), at least 6 hours after an insulin bolus for carbohydrate).
3. Average glycaemic control as measured by HbA1c.
Clinical measures 1. Change in auxological parameters (height, weight, BMI z-score).
2. Change in total daily dose, including basal and bolus proportion, carbohydrate ratios and insulin
sensitivity.
Psychosocial 
(refer to table 3 for 
details)
1. Fear of hypoglycaemia.
2. Hypoglycaemia awareness.
3. Anxiety.
4. Impact and satisfaction.
5. Quality of life.
6. Diabetes specific quality of life.
7. Diabetes distress.
Semistructured interview.
Human–technology 
interaction
1. Assess participant technology interaction and explore adherence patterns and approaches that
may improve it.
Health-economic 1. Assess the health economic impact of the MiniMed 670G.
Biomarkers (refer to 
box 1 for details)
1. Assess the impact of the MiniMed 670G Insulin Pump Hybrid Closed-Loop System on panel of
biomarkers (see box 1).
Performance 
parameters
1. Proportion of time hybrid closed loop is active.
2. Unplanned exits from closed loop (n).
3. Sensor performance—mean absolute relative difference (MARD), sensor failures (n).
4. Insulin delivery line failures.
Safety 1. Hospitalisations rate for diabetic ketoacidosis.
2. Episodes of severe hypoglycaemia over (defined having altered mental status and cannot assist
in their care, is semiconscious or unconscious or in coma±convulsions and may require parenteral
therapy (glucagon or intravenous glucose).
Healthcare provider 
experiences
1. Tracking expectations of HCL system through the study.
BMI, body mass index; CGM, continuous glucose monitoring; HbA1c, haemoglobin A1c; HCL, hybrid closed loop. 
box 1 biomarkers
 ► Cell adhesion molecules (CAM)S
 ► Soluble vascular cell adhesion molecules (sVCAM)
 ► Soluble intercellular adhesion molecules (sICAM)
 ► E-Selectin
 ► Oxidised low-density lipoprotein
 ► Myeloperoxidase
 ► MicroRNA signatures for arterial, renal and retinal complications
 ► Telomerase
 ► DNA methylation/acetylation
 ► GlycoMark
 ► Isoprostanes and proteomics
 ► Clotting profile
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study, there were 97 subjects aged 12–<25 years who used 
injections or pumps at enrolment, and had a baseline 
HbA1c value <10.5%; participants were randomised to 
the control group (usual care), and had blinded CGM 
data at randomisation and at 6 months. The effective 
SD (after adjusting for baseline) was 13%. Assuming 
parallel groups, normal distribution for the treatment 
effect, a 1:1 allocation, a two-tailed test with null hypoth-
esis stating that the difference is zero, no corrections for 
multiple comparisons, and a type I error=5%, 158 partic-
ipants are required to detect an absolute 7% difference, 
using an SD of 13%, and 85% power (allowing for 20% 
predicted dropout). Outpatient data from trials to date 
typically show an improvement of 10%–20% for time in 
target range12; however, our recruitment pool typically 
has better glucose control at baseline in comparison to 
these studies.
A data safety monitoring board (DSMB) will meet 
quarterly, who will define stopping rules as part of their 
mandate.
hCL system
The intervention arm will use the MiniMed 670G insulin 
pump, coupled with a fourth-generation glucose sensor 
and GST3C transmitter (defined as HCL during the 
trial). The closed-loop algorithm is contained in the 
MiniMed 670G insulin pump, using a modified PID 
model, with insulin feedback and additional safety 
features. The algorithm receives CGM data every 5 min, 
and a ‘basal rate’ insulin delivery is computed and 
adjusted every 5 min. Therefore, standard ‘basal’ insulin 
that is preprogrammed in regular insulin pump therapy 
is replaced by the algorithm-derived insulin delivery 
(given as a microbolus every 5 min). When the algo-
rithm is controlling insulin delivery, it is termed ‘Auto 
Mode’. Meals will still be announced, and an insulin 
bolus delivered according to the individualised patient 
carbohydrate ratio and insulin sensitivity factor (should 
a correction bolus be required in addition to the insulin 
for carbohydrate).
Blinded CGM will be collected three times during the 
study (baseline: at visit 3 for 3 weeks, midpoint: prior 
to visit 11 for 2 weeks, and prior to end for 3 weeks). A 
fourth-generation sensor will be inserted and a GST3C 
transmitter connected. Participants will be required to 
record finger prick glucose levels at least twice a day. 
CGM data are collected by uploading the GST3C and 
finger prick values from the CONTOUR NEXT LINK 2.4 
from Bayer.
All participants will be issued with the CONTOUR 
NEXT LINK 2.4 from Bayer. This glucose monitor 
requires CONTOUR PLUS test strips. For participants 
randomised to HCL, this allows for data to be directly 
sent to the insulin pump. For participants not on HCL, 
the CONTOUR NEXT LINK 2.4 will be used in addition 
to their regular metre during CGM collection.
Carelink is a Medtronic web-based platform which is 
used for uploading insulin pump data. The Medtronic 
670G can be uploaded, using the CONTOUR NEXT 
LINK 2.4, which is plugged into the Universal Serial Bus 
port of a personal computer. The software is Apple and 
Table 2 Inclusion and exclusion criteria
Summary of eligibility 
criteria
1. Type 1 diabetes (diagnosis consistent with American Diabetes Association Classification of
Diabetes Mellitus) diagnosed at least 1 year ago.
2. Fasting C peptide <0.1 nmol/L (in the absence of hypoglycaemia).
3. Insulin regimen either: multiple daily injections (MDI)≥4 injections per day (≥3 rapid-acting insulin
and ≥1 long-acting insulin), or insulin pump therapy (CSII) established for >3 months.
4. Aged 12–<25 years.
5. HbA1c ≤10.5% (91 mmol/mol).
6. Living in an area with internet and cellular phone coverage.
7. English speaking.
Summary of exclusion 
criteria
1. Chronic kidney disease (eGFR <45 mL/min/1.73 m2).
2. Use of any non-insulin glucose-lowering agent within the past 3 months.
3. Oral or injected steroid use within the past 3 months.
4. Pregnancy or planned pregnancy within the study period.
5. Uncontrolled coeliac disease (not following a gluten-free diet), or other untreated malabsorptions.
6. Uncontrolled thyroid disease.
7. Clinically significant gastroparesis.
8. Uncontrolled hypertension (DBP >100 mm Hg and/or SBP >160 mm Hg).
9. History of myocardial infarction, severe uncontrolled heart failure, unstable angina, transient
ischaemic attack (TIA), stroke or thromboembolic disease in the past 3 months.
10. Poor visual acuity precluding use of the investigational technology.
11. Inability or unwillingness to meet protocol requirements (including carbohydrate counting, CGM
use as per allocated study group only).
12. Severe or unstable medical or psychological condition which, in the opinion of the investigator,
would compromise the ability to meet protocol requirements.
CGM, continuous glucose monitor; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, haemoglobin A1c; SBP, 
systolic blood pressure. 
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Windows compatible. Insulin pump data are then acces-
sible for download by the investigators.
study protocol
The study protocol is illustrated in schematic form in 
figure 1.
Visit 1 to visit 5 encompasses the run-in period which is 4 
to 5 weeks in duration. Visit 1 is used to confirm eligibility 
for entry into the study, and for recording demographic 
(age, date of birth), auxological (height, weight) and 
clinical (date of diagnosis, HbA1c, current treatment 
regimen and insulin pump settings if applicable, blood 
pressure) data. A series of age-appropriate psychological 
questionnaires will be administered via an online plat-
form (Qualtrics). The validated questionnaires and the 
frequency of administration are listed in table 3.
Figure 1 Schematic outline of study. CGM, continuous glucose monitor; CHO, carbohydrate; HbA1c, haemoglobin A1c; HCL, 
hybrid closed loop; MDI, multiple daily injections; RCT, randomised controlled trial. 
Table 3 Questionnaires administered during the trial.
Category of questionnaire Specific questionnaire used Visit administered
Fear of hypoglycaemia Hypoglycaemic Fear Survey-II Worry scale: 17–<25 years. Children’s 
Hypoglycaemia Fear Survey 12–17 years.
1, 11, 16
Hypoglycaemia awareness Hypoglycaemia Awareness Scale (Gold Score) 1, 11, 16
Anxiety State–Trait Anxiety Inventory (Child version for 12–15 years, adult 
version≥16–<25 years)
1, 11, 16
Treatment impact and 
satisfaction
The Diabetes Treatment Satisfaction Questionnaire status and 
change version (16–<25 years), teen version (12–16 years)
1, 11, 16 (status version)
16 (change version)
Functional health status EuroQuol-5 Dimension-Youth (EQ-5D-Y) 1, 6, 11, 16
Diabetes specific quality of 
life
Pediatric quality of life (PedsQL)—Child version (12 year olds), 
adolescent version13–18 and young adult version (18 –<25).
1, 11, 16
Diabetes distress Problem Areas in Diabetes (Teen version for 12–17 years, standard 
version≥17–<25 year)
1, 11, 16
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Visit 2 functions as an education review and supple-
mental visits may be required depending on the level of 
prior knowledge. Specifically, carbohydrate counting is 
reviewed until deemed competent by a dietitian, before 
visit 3 can occur. This is to ensure that all participants 
have the capability to operate HCL if randomised to the 
intervention. Visits 3 to 5 are scheduled visits to capture 
3 weeks of baseline CGM data for the primary outcome. 
Participants will be issued with a logbook to record symp-
tomatic hypoglycaemia and time off work by parents or 
school/work for participants. This diary will be kept for 
the duration of the trial.
Randomisation
At visit 6, participants will be randomised to HCL, or 
continue on their current treatment regimen. Partic-
ipants will be allocated using minimisation with the 
following balancing factors: time in target glucose range 
(above or below 55%), sex, age, duration of diabetes and 
trial site. Participant randomisation is conducted by an 
independent third party (National Health and Medical 
Research Council Clinical Trials Centre, Sydney). Minimi-
sation is a method of ensuring excellent balance between 
groups for known prognostic factors17; further detail on 
the minimisation process can be found elsewhere.18 Allo-
cation concealment in this multisite study is protected 
through the centralised management of participant allo-
cation by an independent third party: recruiters at each 
site do not have access to pooled strata information used 
in the minimisation process; their access is restricted to 
their site participants, protecting allocation concealment 
and reducing the predictability of allocations. While 
the study manager has access to the pooled data, this 
individual is separate from the randomisation process. 
Auxological and clinical parameters are recorded. Addi-
tionally, a fasting blood sample for biomarkers will be 
drawn. The list of biomarkers taken at visits 6 and 16 are 
listed in table 3. Participant flow for the rest of the trial is 
dependent on which group they are randomised to, and 
what baseline treatment regimen they were on.
Participants on MDI and CSII at baseline randomised 
to continue with standard therapy will have a face-to-face 
review at 4 weeks post randomisation for clinical review 
(visit 8). Two weeks of masked CGM collection will occur 
from 11 weeks post randomisation (visits 9 and 10). 
Repeat collection of auxological and clinical data as well 
as questionnaires occurs at the midpoint of the study, 
13 weeks post randomisation (visit 11). At 23 weeks post 
randomisation, a final 3 weeks of masked CGM will be 
collected (visits 12, 13 and 14). The study ends after 26 
weeks, with repeat collection of auxological and clinical 
data, as well as questionnaires, and biomarkers.
Participants on MDI randomised to HCL have educa-
tion on CSII (visit 7A), will return for an observed line 
change 3 days later (visit 7B), receive CGM training 2 
weeks after using the insulin pump (visit 7C) and, after a 
minimum of 3 days using SAP therapy, will be trained on 
and initiate Auto Mode (7D). Thereafter, visit 8 to visit 16 
have the same assessments as those randomised to remain 
on standard therapy.
Participants on CSII randomised to HCL are trained 
on using the HCL system (visit 7A), and CGM. After a 
minimum of 3 days, the participant will be trained on and 
initiate Auto Mode (visit 7B). Thereafter, all visits are the 
same as for those randomised to standard therapy.
Participants who are using CGM as part of their stan-
dard therapy, or as part of the HCL system will need to 
wear a second masked CGM for consistency during the 
masked CGM collection phases.
From randomisation (visit 6), all participants will have 
an application installed on their smart phone (if available) 
for repeated sampling (weekly) of participant experiences 
of various aspects of daily living, including exercise, sleep, 
socialising, food and HCL-specific responses directed at 
trust and usability. The series of questions takes less than 
1 min to respond on a Likert scale. A similar application 
with a different set of questions will assess experiences 
and expectations of HCL in healthcare professionals 
involved in the trial.
A subset of participants at the primary site (Princess 
Margaret Hospital) will be approached for a semistruc-
tured interview after the study is complete.
data management and monitoring
Once enrolled, participants will be allocated a unique 
identifying number. A centralised database, managed at 
Princess Margaret Hospital, will collate all data input from 
study visits, questionnaires, insulin pumps, CGM and the 
mobile application with weekly sampling. The database 
will be kept on a secure server, with password protection.
A DSMB will be appointed for data review. Adverse 
events are defined as any undesirable clinical occurrence 
in a subject, whether it is considered to be device related 
or not, that includes a clinical sign, symptom or condi-
tion and/or an observation of an unintended technical 
performance or performance outcome of the device, 
and will be evaluated by the local investigator. A serious 
adverse event is defined as one which is fatal or life threat-
ening or requires hospitalisation, including diabetic keto-
acidosis or severe hypoglycaemia. All adverse and severe 
adverse events will be reported to the DSMB and relevant 
ethics committee. The DSMB will provide oversight for 
this study, and the aligned adult study. The following stop-
ping rules will be adhered to: (1) Systematic hardware 
failure compromising participant safety, for example, 
recurrent diabetic ketoacidosis or injury, (2) systematic 
algorithm-driven severe hypoglycaemia and (3) greater 
than 50% post randomisation dropout.
statistical analysis
A detailed statistical analysis plan will be reported else-
where and, here, we describe the approach for the 
primary outcome only. All statistical analyses will be 
performed using SAS for Windows (SAS Institute) and 
STATA (StataCorp). The analysis population will be the 
intention-to-treat (ITT) population, which will be defined 
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as all participants who are randomised and have at least 
one visit after baseline. P values <0.05 will be considered 
statistically significant and two-sided p values will be 
reported. Descriptive statistics will be used to characterise 
participants at study entry.
The primary endpoint, average % time spent in target 
glucose range (sensor glucose level 3.9–10.0 mmol/L) 
during the final 3-week blinded sensor period, will be anal-
ysed using analysis of covariance (ANCOVA) adjusting for 
baseline percentage score. Least square means and least 
square mean differences and their associated 95% CI 
will be presented for each treatment group and between 
groups. In the event that residuals are not normally distrib-
uted: the Mann-Whitney-Wilcoxon (Wilcoxon rank sum) 
test will be employed if raw data are symmetric; if raw data 
are non-symmetric, bootstrap methods19 will be used to 
test the difference in means. Multiple imputation will be 
used to deal with missing data in the ITT analysis.
Continuous secondary outcomes will be analysed using 
ANCOVA adjusting for baseline values, count outcomes 
will be analysed using Poisson regression (or negative 
binomial regression where overdispersion is apparent) 
and logistic regression will be used for binomial outcomes. 
Non-parametric methods will be used where model fit is 
poor and transformations are unsuccessful. Subgroup 
analysis by baseline insulin regimen will be performed by 
including an interaction term in the regression model-
ling, whereas where non-parametric methods are used, 
subgroup analysis will be performed by stratifying by base-
line insulin regimen.
A separate economic analysis will be conducted using 
costs (resource units) and measures of functional health 
status (using the EuroQuol-5 Dimension-Youth (EQ-5D)) 
collected during the trial to estimate incremental cost-ef-
fectiveness of automated insulin delivery compared with 
standard treatment. A health economics protocol will be 
published independently as this paper is focused on the 
primary outcome.
No corrections for multiplicity are planned; rather, a 
transparent approach to reporting results will be taken, 
with all effects, CI and p values for the primary and 
secondary outcomes being presented.20
dIsCussIon
HCL is an important advancement in the management of 
T1D, and has potential to improve glycaemic and quality 
of life outcomes. There are several international multi-
centre randomised outpatient trials investigating the effi-
cacy and safety of automated insulin delivery currently 
underway (as registered at https:// clinicaltrials. gov). 
The point of difference of this study (and the aligned 
adult study) is that these are the first studies to compare 
HCL with standard care—including participants using 
MDI and CSII, with or without adjunctive CGM. The 
justification for a heterogeneous standard care control 
arm is that this study will provide comparative data for all 
people with T1D when considering the option of using 
HCL. By representing the diverse treatment options 
that are currently in use by people with T1D, the data 
from the study will better inform the role of HCL in 
the general T1D clinic, allowing clinicians and patients 
to make evidence-based decisions. Careful attention to 
education in the run-in phase will reduce the possible 
bias created by potential unequal contact time with 
research staff favouring participants randomised to HCL. 
This will add strength to the planned health economic 
evaluation which in turn will inform funding decisions 
to facilitate access to these technologies in the future. 
The inclusion of MDI as a comparative arm in diabetes 
technology studies has precedent.21 This study in those 
aged 12–<25 years is complemented by a parallel study 
being conducted in seven adult centres across Australia in 
people aged greater than 25 years with T1D.
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